Стандарты терапии псориатического артрита
https://doi.org/10.14412/1995-4484-2009-1310
Аннотация
Псориатический артрит (ПсА) – хроническое воспалительное заболевание суставов, позвоночника и энтезисов из группы серонегативных спондилоартритов, обычно ассоциированное с псориазом [1]. Считают, что заболевание возникает в результате сложных взаимодействий между генетическими, иммунологическими и внешнесредовыми факторами.
Список литературы
1. <div><p>Moll J. M. H., Wright V. Psoriatic arthritis. Semin. Arthritis Rheum., 1973,3,55–78.</p><p>Melski J. W., Bernhard J. D., Stern R. S. The Koebner (isomorphic) response in psotiasis. Associations with early at onset and multiple previous therapies. Arch. Dermatol., 1983,119, 655-9.</p><p>Scarpa R., Del Puente A., di Girolamo C. et аl. Interplay between environmental factors, articular involvement, and HLA-B27 in patients with psoriatic arthritis. Ann. Rheum. Dis., 1999,51, 78-9.</p><p>Langevitz P., Buskila D., Gladman D. D. Psoriatic Arthritis precipitated by physical trauma. J. Rheumatology, 2006,33(7),1417-56.</p><p>Punzi L., Pianon M., Bertazzolo N. et al. Clinical, laboratory and immunogenetic aspects of post-traumatic psoriatic arthritis: A study of 25 patients. Clin. Exp. Rheumatol., 1998, 16, 277-81.</p><p>Bruce I. N., Silman A. J. The aetiology of psoriatic arthritis. Rheumatology (Oxford), 2001,40, 363-6.</p><p>Rasmussen J. E. The relationship between infection with group A hemolytic streptococci and the development. Pediatr. Inf. Dis., J. 2000,19,153-4.</p><p>Rahman M.U., Ahmed S., Schumacher H. R. et al. High levels of antipeptidoglycan antibodies in psoriatic and other seronegative arthritides. J. Rheumatology,1990,17,621-5.</p><p>Asumalahti K., Veal C., Laitinen T. et.al. Coding Haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum. Mol. Genet., 2002,11,589-97.</p><p>Gladman D.D., Farewell V.T. The role of HLA antigens as psoriatic arthritis indicators of progression in psoriatic arthritis (PsA); multivariate relative risk model. Arthritis Rheum., 1995,25,730-3.</p><p>Gonzalez S., Martinez-Borra J., Torre-Alonso J. C. et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the associationof Cw*0602 in psoriasis. Arthritis Rheum., 1999,42,1010-6.</p><p>Hohler T., Kruger A., Schneider P. M. et.al. A TNF- alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J. Invest. Dermatol., 1997,109, 562-5.</p><p>Cassel S., Kavanaugh A. Psoriatic Arthritis: Pathogenesis and novel immunomodulatory approaches to treatment. J. Imm. Bas. Ther. Vaccines, 2005,3,6- 9.</p><p>Ritchlin C. Pathogenesis of Psoriatic Arthritis. Curr. Opin. Rheum., 2005,17, 406-12.</p><p>Mease P. J. Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann. Rheum. Dis., 2002, 61, 298-304.</p><p>Reece R. J., Canete J. D., Parsons W. J. et al. Distinct vascular patterns in the synovitis of psoriatic, reactive and rheumatoid arthritis. Arthritis Rheum., 1999, 42(7), 1481-4.</p><p>Fearon U., Griosiose K., Fraser A. et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J. Rheumatology, 2003, 30, 260-8.</p><p>Peters R. Vascular endothelial growth factor and the angiopoietins. Working together to build a better blood vessel. Circul. Res., 1998, 83, 342-3.</p><p>Fearon U., Reece R.J., Blythe D. et al. Synovial cytokine and growth factor regulation of MMPs/ TIMPs: implication for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann. N. Y. Acad. Sci., 1999,872, 619-21.</p><p>Creamer D.J., Jaggar R., Allen M. et al. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br. J. Dermatol., 1997, 137, 851-5.</p><p>Kuroda K.S., Sapadin A., Shoji T. et al. Altered expres- sion of angiopoietins and Tie 2 endothelium receptor in psoriasis. J. Inves. Dermatol., 2001,116(5), 713-20.</p><p>Canete J., Pablos J., Sanmarti R. et al. Antiangiogenic effect of anti-Tumor Necrosis Factor α therapy with Infliximab in psotiatic arthritis. Arthritis Rheum., 2004, 50(5), 1636-41.</p><p>Cordiali-Fei P., Trento E., D,Agosto G. et al. Effective therapy with anti-TNF-α in psotiatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann. N. Y. Acad. Sci., 2007, 1110, 578-89. 35</p><p>Fraser A. D., van Kuijk A.W., Westhovens R. et al. A randomized, double blind, placebo controlled, multicentre triale of combination therapy with methotrexate plus cyclosporine in patients with active psotiatic arthritis. Ann. Rheum. Dis., 2005, 64, 859-64.</p><p>Moll J. M. H., Wright V. Psoriatic arthritis. Semin. Arthritis Rheum., 1973, 3, 55–78.</p><p>Mease P. J., Helliwell P. S. (Editors). Atlas of Psoriatic Arthritis. Springer (London) 2008, 118.</p><p>Тaylor W., Gladman D., Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum., 2006,54, 2665–73.</p><p>Chandran V., Schentag C., Gladman D. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum., 2007, 57(8), 1560-63</p><p>Oliveri I., Barozzi L., Favaro L. et al. Dactilitis in patients with seronegative spondylarthropathy. Assesment by ultrasonograhy and magnetic resonance imaging. Arthritis Rheum., 1996, 39, 1524–8.</p><p>Kane D., Greaney T., Bresnihan B. et. al. Ultrasonography in the diagnosis and manegment of psoriatic dactilitis. J. Rheumatology, 1999, 26, 1746- 51.</p><p>Healy P., Helliwell Ph. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum., 2008, 5(59), 686–91.</p><p>MgGonald D., Gibbon W., Emery P. Classification of inflammatory arthritis.by enthesitis. Lancet, 1998, 352, 1137-40.</p><p>Salonen D. C., Brower A. C. et al. Seronegative spon- dyloarthropathies: imaging. Edited by Hochberg M. C., Silman A. J., Smolen J. S. Philadelphia: Mosby, 2003, 1193-204.</p><p>Khan M., Schentag C., Gladman D. D. Clinical and radiological changes during psoriatic arthritis disease progression. J. Rheumatology, 2003, 30, 1022-26.</p><p>Veale D., Rogers S., Fitzgerald O. Classification of subset in psoriatic arthritis. Br. J. Rheumatol., 1994, 33, 133-8.</p><p>Gladman D. D, Shuckett R., Russell M.L. et.al. Psoriatic arthritis – clinical and laboratory analysis of patients. Q. J. Med., 1987, 62, 127-41.</p><p>Lambert J. R., Wright V. Eye inflammation in psoriatic arthritis. Ann. Rheum. Dis., 1976, 35, 354-6.</p><p>Queiro R., Torre J. C., Belzunegui J. et. al. Clinical features and predictive factors in psoriatic arthritis uveitis. Semin. Arthritis Rheum., 2002, 31, 264-70.</p><p>Wong K., Gladman D. D., Husted J., et. al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic 1. Causes and risk of death. Arthritis Rheum., 1997, 40, 1868–72.</p><p>Cantini F., Niccoli L., Nannini C. et al. Frequency and duration of clinical remission in patients with peripherial psoriatic arthritis requiring second-line drugs. Rheumatol., 2008, 9, 1-5. 36 41.</p><p>Ritchlin C. T. Therapies for psoriatic enthesopathy. A systematic review. J. Rheumatology, 2006, 33, 1435- 8.</p><p>Stafford L., Kane D., Murphy E. et al. Psoriasis predicts a poor short-term outcome in patients with spondyloarthropathy Arthritis Care Res., 2001, 45, 485-93.</p><p>Kavanaugh A., Ritchlin C. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Systematic Review of Treatments of Psoriatic Arthritis. J. Rheumatology, 2006, 33 (7), 1417-56.</p><p>Kyle S., Chandler D., Griffiths C. E. et al. Guideline for anti-TNF-α in psoriatic arthritis. Rheumatol., 2005, 44, 390-7.</p><p>Tukriewicz A., Moreland L. Psoriatic Arthritis. Current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum., 2007, 56(4), 1051-66.</p><p>Gottlieb A., Korman N., Gordon K. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J. Am. Acad. Dermatol., 2008, 58(5), 851- 64.</p><p>Soriano E., McHugh N. Therapies for perepheral joint disease in psoriatic arthritis. A systematic Review. J. Rheumatology, 2006, 33,1-7.</p><p>Sarzi-Puttini P., Santandrea S., Boccasini L. et. al. The role of NSADI in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin. Exper. Rheumatol., 2001, 19, suppl 22, S17-S20.</p><p>Lassus A. A. A comparative pilot study of azapropa- zone and indomethacin in the treatment of psoriatic arthritis and Reiter,s disease. Curr. Med. Res. Opin., 1976, 4, 65-9.</p><p>Lonauer G., Wirth W. Controlled double blind study on the effectiveness and adverse effects of acemetacin and indomethacin in the treatment of psoriatic arthri- tis. Arzneimittelforshung 1980, 30, 1440-4.</p><p>Leathham P. A., Bird H. A., Wright V. et al. The run-in period in trial design: a comparison of two non-steroidal anti-inflammatory agents in psoriatic arthropathy. Agent. Actions., 1982,12, 221-4.</p><p>Hopkins R., Bird H. A., Jones H. et al. A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann. Rheum. Dis., 1985, 44,189- 93.</p><p>Powles A. V., Griffiths C. E., Seifert M. H. et al. Exacerbation of psoriasis by indomethacin. Br. J. Dermatol., 1987, 117, 799-800.</p><p>Pipitоne N., Kingsley G. H., Manzo A. et al. Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatol., (Oxford), 2003, 42, 1138-48.</p><p>Gladman D. D., Farewell V. T., Nadeau C. Clinical indicators of progression on psoriatic arthritis: multivariate relative risk model. J. Rheumatology, 1995, 22, 675-9.</p><p>Cleg D.O., Reda D. J., Mejias E. et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis patients. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum., 1996, 39, 2013- 20.</p><p>Gupta A. K., Grober J. S., Hamilton T. A. et al. Sulfasalazine therapy for psoriatic arthritis: a double blind placebo controlled trial. J. Rheumatology, 1995, 22, 894-8.</p><p>Combe B., Goupille P., Hamilton T. A. et al. Sulfasalazine in psoriatic arthritis: a randomized, multicenter, placebo – controlled study. Br. J. Rheum., 1996, 35, 664-8.</p><p>Rahman P., Gladman D. D., Cook R. J. et al. The use of sulfasalszine in psoriatic arthritis: clinical experience. J. Rheumatology, 1998, 18, 27-33.</p><p>Salvarani C., Macchioni P., Olivieri I. et al. A Comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J. Rheumatology, 2001, 28, 2274-82.</p><p>Willkens R. F., Williams H. J., Ward J. R. Randomized, double blind placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum., 1984, 27, 376-81.</p><p>Gladman D. D., Strand V., Mease P. et. al. OMERACT psoriatic arthritis workshop: synopsis. Ann. Rheum. Dis., 2005, 64, (suppl 2), ii115-6.</p><p>Jones G., Grotty M., Brooks P. Interventions for treating psoriatic arthritis (Cochrane Review), In the Cochrane Library, issue 2, 2004; Oxford Update Software.</p><p>Zachariae H., Zachariae E. Methotrexate treatment of psoriatic arthritis. Acta. Derm. Venerol., 1987, 67, 270-3.</p><p>Espinoza L. R., Zakraoui L., Espinoza L. R. Psoriatic arthritis: clinical response and side effects to Methotrexate therapy. J. Rheumatology, 1992, 19, 872-7.</p><p>Abu-Shakra M., Gladman D. D., Thorne J. C. et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J. Rheumatology, 1995, 22, 241-5.</p><p>Fraser A. D., van Kuijk A. W. R., Westhovens R. et al. A randomized, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann. Rheum. Dis., 2005, 64, 859-64.</p><p>Kaltwasser J. P., Nash P., Gladman D. D. et al. Treatment of psoriatic arthritis study group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multionational, double- blind, randomized, placebo – controlled clinical trial. Arthritis Rheum., 2004, 50, 1939-50.</p><p>Cuchacovich M., Soto L. Leflunomide decreases joint erosion and induces reparative changes in a patients with psoriatic arthritis. Ann. Rheum. Dis., 2001, 60, 913-23.</p><p>Sparado A., Riccieri V., Sili-Scavalli A. et al. A Comparison of cyclosporine and methotrexate in the treatment of psoriatic arthritis: a one – year prospective study. Clin. Exp. Rheum., 1995,13, 589-93.</p><p>Macchioni P., Boiardi L., Cremonesi T. et al. The relationship between serum-soluble interleuikin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporine-A. Rheum. Int., 1998, 18, 27-33.</p><p>Ravindran V., Scott D.L., Choy E. H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann. Rheum. Dis., 2008, 67, 855-9.</p><p>Salvarani C., Oliveri I., Pipitone N. et al. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF- α blocking) agents in the treatment in psoriatic arthritis of pso- riatic arthritis. Clin. Exp. Rheum., 2006, 24, 70-8.</p><p>Etanercept and infliximab for the treatment of adults with psoriatic arthritis. N. H. S, 2007.</p><p>Sattar N., Crompton Ph., Cherry L. et al. Effects of Tumor Necrosis Factor Blocade on Cardiovascular Risk Factor in Psoriatic arthritis. A double-blind, placebo–controlled Study. Arthritis Rheum., 2007, 56(3), 831-9.</p><p>Canete J., Pablos J., Sanmarti R. et al. Antiangiogenic Effects of Anti-Tumor Necrosis Factor Therapy With Infliximab in Psoriatic arthritis. Arthritis Rheum., 2004, 50(5), 1636-41.</p><p>Cordiali-Fei P., Trento E., D’Agosto G. et al. Effective therapy with anti-TNF-alpha in psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann. N. Y. Acad. Sci., 2007, 1110, 578-89.</p><p>Antoni C., Kavanaugh A., Kirkhan B. et al. Sustained benefits of infliximab therapy for dermatological and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 2005, 52, 1227-36.</p><p>Antoni C., Krueger G.G., de Vlam K. et al. IMPACT Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT Trial. Ann. Rheum. Dis., 2005, 64, 1150-7.</p><p>Mease P., Gladman D., Ritchlin C. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum., 2005, 52(10), 3279-89.</p><p>Gladman D., Mease P., Rithlin Ch. et al. Adalimumab for Long-Term Treatment of Psoriatic Arthritis. Forty- Eight Week Data From the Adalimumab Effectiveness in Psoriatic ArthritisTrial. Arthritis Rheum., 2007, 56(2), 476-88.</p><p>Gladman D., Mease P., Rithlin Ch. et al. Adalimumab improves joint-and skin-related functional impairment in patients with psoriatic arthritis: Patients-reported outcomes of the Adalimumab Effectiveness in psoriatic arthritis trials (ADEPT). Ann. Rheum. Dis., 2006, 9, 1-6.</p><p>McHugh N., Van den Bosch F., Manger B. et al. Adalimumab (Humira®) Treatment is Effective in patients with Psoriatic Arthritis (PsA) in Day-to-Day Clinical Practice – Results From the STEREO Trial. 6th Ann. General Meeting of the British Society for Rheumatology (BSR), UK, Liverpool, 2008, abs 259.</p><p>Mease P. J., Thomson G., Klinkhoff A. et al. Psoriatic arthritis patients receiving Adalimumab (Humira®) sustain improvements in health – related quality of life (HRQOL) 144-week results, 9th Annual European League Against Rheumatism, June 11-14, 2008; Paris, France, SAT 0449.</p><p>Mease P. J., Ory P., Sharp J. T. et al. Adalimumab (Humira®) sustains inhibition of joint damage for more than 2 years in patients with Psoriatic Arthritis (PsA), 9th Annual European League Against Rheumatism, June 11-14, 2008, Paris, France, OP-0163.</p><p>Van den Bosch F., Manger B., Goupille P. et al. Clinical remission in patients with Psoriatic Arthritis (PsA) treated with Adalimumab (Humira®). Results of the Stereo trial. 6th Biennial International Congress on Spondyloarthropathies; October 2-4, 2008; Ghent, Belgium. Abstract P70.</p><p>Furst D. E., Keystone E. C, Kirkham B., et al. Updeted consensus statement on biological agents for the treat- ment of rheumatic diseases, 2008. Ann. Rheum. Dis., 2008, 67(Suppl. 3), iii2-iii25.</p></div><br />
Рецензия
Для цитирования:
Коротаева Т.В., Насонов Е.Л. Стандарты терапии псориатического артрита. Научно-практическая ревматология. 2009;47(3):29-37. https://doi.org/10.14412/1995-4484-2009-1310
For citation:
Korotaeva T.V., Nasonov E.L. Standards of therapy of psoriatic arthritis. Rheumatology Science and Practice. 2009;47(3):29-37. (In Russ.) https://doi.org/10.14412/1995-4484-2009-1310
Просмотров: 787
Послать статью по эл. почте 